

RESEARCH

Open Access



# Level of 25-hydroxyvitamin D and vitamin D receptor in diabetic foot ulcer and factor associated with diabetic foot ulcers

Ying Tang<sup>1</sup>, Yixuan Huang<sup>1</sup>, Li Luo<sup>1</sup>, Murong Xu<sup>1</sup>, Datong Deng<sup>1</sup>, Zhaohui Fang<sup>2</sup>, Xiaotong Zhao<sup>1\*</sup> and Mingwei Chen<sup>1,2\*</sup>

## Abstract

**Background** At present, there is no clinical study to elucidate the correlation between vitamin D deficiency and the incidence of diabetic foot osteomyelitis (DFO). This study aims to clarify levels of 25-hydroxyvitamin D [25(OH)VD] in peripheral blood and vitamin D receptor (VDR) expression in wound margin tissues (T-VDR) of patients with type 2 diabetes mellitus (T2DM) with diabetic foot ulcer (DFU) and DFO, and to determine its correlation with treatment outcomes of DFU and DFO, and its value as a potential biomarker for the diagnosis of DFU and DFO.

**Methods** 156 T2DM patients with DFU (DFU group), 100 T2DM patients without DFU (T2DM group), and 100 healthy controls (NC group). The DFU group patients were subdivided into DFO (n = 80) and NDFO groups (n = 76). The level of serum 25(OH)VD was measured via chemiluminescence immunoassay, and T-VDR expression level was determined by quantitative real-time PCR.

**Results** The levels of serum 25(OH)VD in the DFU group were significantly lower than the T2DM group [(10.3 (5.8, 18.7) vs 15.7 (8.6, 24.6) ng/mL,  $P = 0.002$ ]. Similarly, the levels of serum 25(OH)VD and T-VDR expression in the DFO group were statistically lower than the NDFO group [9.2 (5.2, 20.5) vs 12.8 (6.9, 22.1) ng/mL,  $P = 0.006$ ], [1.96 (0.61, 3.97) vs 3.11 (1.36, 5.11),  $P = 0.004$ ], respectively. Furthermore, the levels of serum 25(OH)VD and T-VDR expression in DFU patients were positively correlated with the ulcer healing rate of foot ulcer after 8 weeks of treatment ( $P = 0.031$ ,  $P = 0.016$ , respectively). Multivariate logistic regression analysis showed that low level of serum 25(OH)VD was an independent risk factor for DFU and DFO ( $OR_{DFU} = 2.42$ ,  $OR_{DFO} = 3.05$ ,  $P = 0.008$ ,  $0.001$ , respectively), and decreased T-VDR expression level was an independent risk factor for DFO ( $OR = 2.83$ ,  $P = 0.004$ ). Meanwhile, the ROC curve analysis indicated that the AUC of serum 25(OH)VD level for the diagnosis of DFU and DFO was 0.821 (95% CI, 0.754–0.886,  $P < 0.001$ ) and 0.786 (95% CI, 0.643–0.867,  $P < 0.001$ ), respectively. When establishing a diagnosis of DFO, the AUC of T-VDR expression level was 0.703 (95% CI: 0.618–0.853,  $P < 0.001$ ).

**Conclusions** The levels of serum 25(OH)VD and T-VDR expression in DFU and DFO decreased. Serum 25(OH)VD and T-VDR are potentially valuable biomarkers for diagnosis and prognosis of DFU and DFO.

\*Correspondence:

Xiaotong Zhao  
zxt522154846@163.com  
Mingwei Chen  
chmw1@163.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords** Diabetic foot ulcer, Diabetic foot osteomyelitis, 25-Hydroxyvitamin D, Type 2 diabetes mellitus, Vitamin D receptor.

## Introduction

Diabetic foot ulcer (DFU) is a severe chronic complication of diabetes mellitus (DM) and is associated with a remarkably high treatment cost. Approximately 15% of patients with DM are reported to present with DFU at some time in their lives [1]. The presence of DFU in combination with an infection can impede wound healing, and then progress to diabetic foot osteomyelitis (DFO), leading to increased mortality, decreased quality of life, and increased risk of lower limb amputation [2].

Vitamin D is a type of steroid prohormone. The vitamin D receptor (VDR) exists in nearly all tissues in the human body, such as intestines, bones, parathyroid glands, kidneys, reproductive system, immune cells and is particularly abundant in the skin [3]. It is a member of the steroid hormone receptor superfamily and can regulate the expression of corresponding target genes after being activated. In vitro studies have revealed that a high concentration of vitamin D can upregulate the VDR expression. Several types of vitamin D are currently known, among which vitamin D<sub>3</sub> has the highest activity. Vitamin D<sub>3</sub> undergoes two steps of hydroxylation and is converted into 1,25(OH)<sub>2</sub>D<sub>3</sub>; this compound then combines with VDR to exert physiological effects. Although 1,25(OH)<sub>2</sub>D<sub>3</sub> was considered the active form of vitamin D, its level in serum has not been correlated with the systemic levels of vitamin D. Conversely, 25-hydroxyvitamin D (25(OH)VD) level is known to reflect the systemic vitamin D level [4].

According to the previous survey [5], the concentration of 25(OH)VD varies from population to population. Summer is usually higher than winter. The concentration of 25(OH)VD varies according to different geographical locations, latitude, eating habits and environmental climate. However, the most likely reason for the poor status of vitamin D is the insufficient endogenous synthesis caused by insufficient ultraviolet radiation. Research shows that the prevalence of vitamin D insufficiency and deficiency is very high in the general population of the world, and the situation of vitamin D deficiency in DFU patients is more obvious [6]. Some studies have reported that low level of serum 25(OH)VD can increase the risk of DFU and DFU infection [7, 8], and are related to an increase in the risk of amputation or mortality [9]. Additionally, vitamin D has been involved in regulating the healing process of chronic wounds [10], Vitamin D supplementation can promote wound healing in cases of DFU [11]. However, some studies have not reported

a correlation between vitamin D deficiency and the onset of DFU [9, 12]; furthermore, the levels of serum 25(OH)VD were reported to be significantly increased in patients with chronic active DFU [13]. Owing to the complexity of DFU pathogenesis, further investigation of the correlation between vitamin D insufficiency and DFU pathogenesis and its influencing factors is of paramount importance. Additionally, to the best of our knowledge, no clinical studies have attempted to elucidate the correlation between vitamin D deficiency and the incidence of DFO.

Therefore, in the present study, we aimed to further explore the levels of 25(OH)VD in peripheral blood and VDR expression in wound margin tissues of patients with DFU and DFO, and identify its correlation with treatment outcomes of DFU and DFO, including foot ulcer recurrence, healing, and amputation, and its value as a potential biomarker for the diagnosis of DFU and DFO.

## Material and methods

### Study subjects

We included 723 diabetes patients hospitalized in the Department of Endocrinology of the First Affiliated Hospital of Anhui Medical University from January 2019 to January 2021, of which 156 DFU patients were selected as the DFU group. All DFU patients met the following inclusion criteria: (1) the ulcer duration was four weeks or longer; (2) the ulcer area was 2–20 cm<sup>2</sup> and Wagner grade 2–4; (3) the ankle-brachial index (ABI) was 0.4–0.9; and (4) being diagnosed as type 2 diabetes mellitus (T2DM). Diagnose DFU with osteomyelitis based on medical history, physical signs (especially probe examination), and imaging examination results (X-ray or magnetic resonance imaging [MRI]). Based on this, 156 patients with DFU were labeled into two groups: osteomyelitis group (DFO group, n = 80) and non-osteomyelitis group (NDFO group, n = 76). Meanwhile, we selected 100 T2DM patients from the remaining 567 inpatients with diabetes as the control group of DFU (T2DM group). All patients in the T2DM group were hospitalized for further examination and treatment due to polyuria, polydipsia, polyphagia, weight loss, or abnormal increase of fasting blood glucose or glycosylated hemoglobin A1c (HbA1c) found in the physical examination, and there were no foot ulcers, diabetes lower limb atherosclerotic disease, and diabetes peripheral neuropathy. Besides, another 100 healthy individuals who underwent

physical examination at the health management center of our hospital during the study period were selected as the normal control group (NC group). Subjects in the NC group was received 75 g oral glucose tolerance test (OGTT). Normally, a normal test result requires fasting blood glucose (FPG) level is lower than 6.1 mmol/L, and the blood glucose level 2 h after the glucose load is lower than 7.8 mmol/L. Significantly, exclusion criteria for the subjects were with being bedridden for a long time, acute complications related to diabetes, severe heart, liver, and kidney dysfunction, cancerous ulcer wound, parathyroid disease, autoimmune diseases, taking any drugs that affect serum 25 (OH) VD level, such as calcium, vitamin D, oral contraceptives and glucocorticoids, etc., severe septicemia. The above research design is shown in Fig. 1. The study was approved by the medical ethics committee of the First Affiliated Hospital of Anhui Medical University (Ethical batch number P 2018-11-16), and written informed consent was obtained from all subjects.

## Study methods

### Treatment process of DFU

All patients with DFU underwent wound debridement after admission. In the process of debridement, a skilled surgeon used tissue scissors to cut the full-thickness skin tissue within 0.5 cm of the wound edge according to the sampling protocol. All patients with DFU received routine systemic treatment, which included anti-infection treatment, blood pressure regulation, blood glucose reduction, correction of hypoproteinemia, nerve-nutrition treatment, improvement of blood supply to lower extremity wounds, and wound debridement. The above-mentioned procedures were performed to remove blackened necrotic soft tissue and bone tissue. Decompression and continuous negative pressure wound treatment (NPWT) were performed on a case-by-case basis for the patients with DFU. Amputation was decided by a multidisciplinary team (MDT) of diabetic foot after consultation; the factors that affected the final decision were changes in the patient's condition during the follow-up period; in addition, complete epithelial healing of the wound was observed after 8 weeks of treatment [14]. Briefly, if the wound epithelium is completely healed within 8 weeks or less, the wound is judged to be healed. If the wound epithelium is not completely healed for more than 8 weeks, the wound is judged to be not healed.


### Collection of general information

We measured the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the subjects and recorded the season at the time of enrollment and the mean duration of exposure to sunshine in the recent 3 months. Data related to new or recurrent foot ulcers, smoking habits,

and alcohol consumption were recorded. Regular smoking was defined as smoking at least 1 cigarette a day for a mean duration of >6 months. Chronic alcohol consumption was defined as consuming more than 40 g of ethanol per day for men and 20 g per day for women for more than 5 consecutive years. The severity of DFU infection (mild, moderate, and severe) was assessed according to the recommendations of the Infectious Disease Society of America (IDSA) [15]. The ulcer area was measured via digital photography combined with Image J Medical Image analysis software (Image J-IJ133-JDK15, National Institutes of Health, Bethesda, USA). ABI was measured using a Doppler blood flow detector (DPL-03, Hangzhou Yuanxiang Medical, China). The transcutaneous oxygen pressure (TcPO<sub>2</sub>) in the vicinity of the ulcer was measured using a TcPO<sub>2</sub> monitor (TCM 400, Denmark).

### Detection of observation indices

After fasting for 10 h, we collected blood from the median vein of the elbow in the fasting state from 8:00 am to 8:30 am of the next day to determine liver and kidney function, blood glucose levels, blood lipid composition, HbA1c levels, white blood cell (WBC) count, c-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum 25(OH)VD, serum-free calcium, IL-6, IL-10, and parathyroid hormone (PTH), among other indicators (See Additional file 2: Table S1 for detailed determination method). Estimated glomerular filtration rate (eGFR) was used to evaluate renal function.  $eGFR (ml/min / 1.73 m^2) = 186 \times (Scr^{-1.154}) \times (age^{-0.203}) \times [0.742 (female)]$  [16]. Vitamin D nutritional status was categorized as deficiency, insufficiency, and adequacy when vitamin D levels were <20 ng/mL (<50 nmol/L), 20–30 ng/mL (50–75 nmol/L), and >30 ng/mL (>75 nmol/L), respectively [17]. Additionally, quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the levels of VDR mRNA (T-VDR), IL-6 mRNA (T-IL-6), and IL-10 mRNA (T-IL-10) in wound margin tissues. RNA was extracted from 50 mg of wound edge tissue according to the manufacturer instructions of the miRcute miRNA Extraction and Isolation Kit (Tiangen Biochemical Technology Co., LTD, Beijing, China). The cDNA was then synthesized according to the manufacturer instructions of the miRcute miRNA cDNA Synthesis Kit (Tiangen Biochemical Technology Co., LTD., Beijing, China). Finally, qRT-PCR was performed according to the manufacturer's instructions of the miRcute miRNA fluorescence quantitative detection kit (See Additional file 3: Table S2 for specific primers and reaction conditions). The relative levels of T-VDR,



**Fig. 1** Research design drawing. *NC* normal control group, *T2DM* type 2 diabetes mellitus group, *DFU* diabetic foot ulcer, *DFO* diabetic foot osteomyelitis, *NDFO* diabetic foot ulcer without osteomyelitis, *PTH* parathyroid hormone, *25(OH)VD* 25-hydroxyvitamin D, *Vit D* vitamin D, *IL-6* interleukin-6, *IL-10* interleukin-10, *VDR* vitamin D receptor

T-IL-6, and T-IL-10 were calculated using the  $2^{-\Delta\Delta Ct}$  method with GAPDH as the internal reference.

### Statistical analyses

Statistical software SPSS22.0 (Chicago, IL, USA) was used for data analysis. Measurement data with normal distribution were expressed as mean  $\pm$  standard deviation, and measurement data with non-normal distribution were expressed as median (interquartile range) [M ( $P_{25}$ ,  $P_{75}$ )]. The Student's t-test and the Mann-Whitney U test were used to compare normally and non-normally distributed data. Analysis of variance was used for comparison among multiple groups, and the LSD-T test was used for further pairwise comparison. Enumeration data were expressed as a percentage and the  $\chi^2$  test was performed. Pearson correlation analysis was used to evaluate the association between the levels of serum 25(OH)VD and T-VDR expression and other clinical variables. Multivariate logistic regression was used to determine the risk factors of DFU and DFO. Receiver operating characteristic (ROC) curve analysis was used to investigate the potential biomarkers for the diagnosis of DFU and DFO. All tests were bilateral, and a  $P$ -value of  $<0.05$  indicated statistical significance.

## Results

### Comparisons in clinical parameters of NC group, T2DM group, DFU group

No significant differences were observed in terms of sex, age, smoking habits, alcohol consumption, the proportion of subjects enrolled in winter, mean sunshine duration per day in the recent 3 months, SBP, DBP, TCH, LDL-C, PTH, IL-10 levels in peripheral blood (P-IL-10), and serum ionized calcium levels among the NC, T2DM, and DFU groups ( $P>0.05$ ). On the one hand, compared with the NC group, the levels of FPG, HbA1c and TG in the T2DM and DFU groups were significantly increased, and the proportion of vitamin D deficiency and insufficiency were significantly increased ( $P<0.05$ ). Otherwise, the levels of HDL-C and serum 25(OH)VD were decreased significantly ( $P<0.05$ ). On the other hand, compared with the T2DM group, the duration of diabetes, FPG, HbA1c, TG, CRP, IL-6 levels in peripheral blood (P-IL-6), WBC, and ESR levels appeared to increase significantly in the DFU group ( $P<0.05$ ), while the mean sunshine duration per day in the recent 3 months, eGFR, serum albumin, hemoglobin, serum 25(OH)VD, TcPO2, ABI levels significantly decreased ( $P<0.05$ ). In particular, serum 25(OH)VD levels in the DFU group were statistically lower than the T2DM group [10.3 (5.8, 18.7) vs 15.7 (8.6, 24.6) ng/mL,  $P=0.002$ ] (Table 1). Additionally, in the present study, with the increase of Wagner grade, the

detection rate of vitamin D deficiency and insufficiency in DFU increased significantly ( $\chi^2=40.31$ ,  $P<0.001$ ). Similarly, with the increase of infection severity, the detection rate of vitamin D deficiency and insufficiency in DFU also increased correspondingly ( $\chi^2=23.86$ ,  $P<0.001$ ). In particular, the proportion of vitamin D deficiency and insufficiency in Wagner IV and severely infected DFUs was 100% (Additional file 4: Table S3).

### Comparisons in clinical parameters between NDFO group and DFO group

Compared with the NDFO group, the duration of diabetes, the duration of foot ulcer, Wagner grade, infection severity, the proportion of foot ulcer recurrence, the proportion of drug-resistant bacteria detected in the wound, the proportion of vitamin D deficiency, FPG, HbA1c, CRP, WBC, ESR, P-IL-6, and T-IL-6 in the DFO group were significantly increased ( $P<0.05$ ). However, the mean sunshine duration per day in the recent 3 months, eGFR, serum ALB, Hb, serum 25(OH)VD level, P-IL-10 level, TcPO2, ABI, T-IL-10, and T-VDR expression level appeared to decrease significantly ( $P<0.05$ ). In addition, the levels of serum 25(OH)VD and T-VDR expression in the DFO group were statistically lower than the NDFO group [9.2 (5.2, 20.5) vs 12.8 (6.9, 22.1) ng/mL,  $P=0.006$ ], [1.96 (0.61, 3.97) vs 3.11 (1.36, 5.11),  $P=0.004$ ], respectively. From the analysis above, there were no significant differences between the NDFO group and the DFO group in terms of other clinical parameters ( $P>0.05$ ) (Table 2).

### Relationship between the levels of serum 25(OH)VD and T-VDR expression and the clinical features of DFU and DFO patients

In order to further study the clinical significance of changes in the levels of serum 25(OH)VD and T-VDR expression, median values of the levels of serum 25(OH)VD and T-VDR expression of patients with DFU and DFO were used as the cutoff points for grouping (The cut-off point of the levels of serum 25(OH)VD and T-VDR expression for grouping were 10.3 ng/mL and 2.68, respectively), and furthermore, the low-expression group (lower than the cut-off point) and high-expression group (higher than or equal to the cut-off point). Based on the comparison of the clinical characteristics of the two groups of DFU, the levels of serum 25(OH)VD and T-VDR expression were negatively correlated with the duration of foot ulcer disease, Wagner grade, the severity of wound infection, the detection rate of drug-resistant bacteria, the recurrence rate of foot ulcer, and amputation rate of foot ulcer ( $P<0.05$ ), and positively correlated with the healing rate of foot ulcer after 8 weeks ( $P<0.05$ ). No correlation was observed between the levels of serum

**Table 1** Comparisons in clinical parameters among NC group, T2DM group, and DFU group [n (%), ( $\pm$ s), M (P25, P75)]

| Variable                                       | NC group<br>(n = 100) | T2DM group<br>(n = 100)      | DFU group<br>(n = 156)          | P value |
|--|-----------------------|------------------------------|---------------------------------|---------|
| Sex (male/female)                              | 100(57/43)            | 100(54/46)                   | 156 (88/68)                     | 0.899   |
| Age (year)                                     | 55.1 $\pm$ 11.9       | 54.9 $\pm$ 12.3              | 55.6 $\pm$ 11.2                 | 0.581   |
| Duration of diabetes (year)                    | –                     | 0.4 $\pm$ 0.2                | 12.1 $\pm$ 6.4 <sup>d</sup>     | < 0.001 |
| Duration of ulcers (week)                      | –                     | –                            | 7.2 $\pm$ 2.6                   | –       |
| Smoking habits                                 | 44 (44.0)             | 48 (48.0)                    | 80 (51.3)                       | 0.522   |
| Alcohol consumption                            | 23 (23.0)             | 26 (26.0)                    | 43 (27.6)                       | 0.717   |
| Mean sunshine time per day (h)                 | 4.1 (1.9, 6.3)        | 3.9 (1.7, 6.1)               | 2.8 (1.2, 5.7) <sup>bd</sup>    | 0.002   |
| Winter enrollment                              | 39 (39.0)             | 40 (40.0)                    | 69 (44.2)                       | 0.661   |
| Wagner grade (2/3/4)                           | –                     | –                            | 20/108/28                       | –       |
| Severity of infection (mild/ moderate/ severe) | –                     | –                            | 20/94/42                        | –       |
| First episode/ recurrence of foot ulcer        | –                     | –                            | 105/51                          | –       |
| SBP (mm Hg)                                    | 122 $\pm$ 11          | 127 $\pm$ 13                 | 132 $\pm$ 14                    | 0.082   |
| DBP (mm Hg)                                    | 74 $\pm$ 12           | 78 $\pm$ 13                  | 82 $\pm$ 14                     | 0.078   |
| FPG (mmol/L)                                   | 4.9 $\pm$ 0.5         | 9.8 $\pm$ 2.4 <sup>b</sup>   | 12.3 $\pm$ 2.7 <sup>bd</sup>    | < 0.001 |
| HbA1c (%)                                      | 5.2 $\pm$ 0.4         | 8.5 $\pm$ 1.7 <sup>b</sup>   | 9.3 $\pm$ 1.6 <sup>bc</sup>     | < 0.001 |
| TG (mmol/L)                                    | 1.4 $\pm$ 0.6         | 1.8 $\pm$ 0.6 <sup>b</sup>   | 2.2 $\pm$ 0.7 <sup>bc</sup>     | 0.021   |
| TCH (mmol/L)                                   | 4.2 $\pm$ 0.7         | 4.9 $\pm$ 0.6                | 4.6 $\pm$ 0.7                   | 0.558   |
| LDL-C (mmol/L)                                 | 2.5 $\pm$ 0.3         | 2.9 $\pm$ 0.4                | 2.8 $\pm$ 0.5                   | 0.318   |
| HDL-C (mmol/L)                                 | 1.5 $\pm$ 0.2         | 1.2 $\pm$ 0.3 <sup>a</sup>   | 0.9 $\pm$ 0.3 <sup>bc</sup>     | < 0.001 |
| PTH (pg/mL)                                    | 14.5 $\pm$ 4.2        | 15.1 $\pm$ 5.3               | 17.8 (10.5,42.4)                | 0.274   |
| Serum ionic calcium (mmol/L)                   | 0.92 $\pm$ 0.22       | 0.89 $\pm$ 0.19              | 0.86 $\pm$ 0.16                 | 0.652   |
| eGFR (ml/min/1.73m <sup>2</sup> )              | 104.4 $\pm$ 16.5      | 98.4 $\pm$ 10.2              | 75.7 $\pm$ 15.6 <sup>bc</sup>   | < 0.001 |
| ALB (g/L)                                      | 45.2 $\pm$ 3.2        | 44.2 $\pm$ 3.5               | 37.2 $\pm$ 4.8 <sup>bc</sup>    | 0.014   |
| Hb (g /L)                                      | 134.4 $\pm$ 8.4       | 129.4 $\pm$ 10.2             | 113.7 $\pm$ 12.6 <sup>bc</sup>  | 0.028   |
| TcPO2 (mmHg)                                   | 76.4 $\pm$ 7.2        | 70.5 $\pm$ 8.9               | 48.5 $\pm$ 10.2 <sup>bd</sup>   | < 0.001 |
| ABI  | 1.15 $\pm$ 0.14       | 1.04 $\pm$ 0.19              | 0.74 $\pm$ 0.29 <sup>bd</sup>   | < 0.001 |
| CRP ( mg/L)                                    | 6.5 $\pm$ 0.9         | 7.1 $\pm$ 1.0                | 46.8 (27.5, 92.4) <sup>bd</sup> | < 0.001 |
| WBC ( $\times 10^9$ )                          | 4.3 $\pm$ 0.5         | 4.7 $\pm$ 0.6                | 11.5 $\pm$ 4.3 <sup>bd</sup>    | < 0.001 |
| ESR (mm/h)                                     | 12.6 $\pm$ 1.3        | 12.8 $\pm$ 2.2               | 33.8 (25.9, 89.5) <sup>bd</sup> | < 0.001 |
| 25(OH)VD (ng/mL)                               | 23.8 (15.7,33.7)      | 15.7 (8.6,24.6) <sup>a</sup> | 10.3(5.8, 18.7) <sup>bc</sup>   | < 0.001 |
| Vit D status                                   |                       |                              |                                 | < 0.001 |
| Deficiency                                     | 28 (28.0)             | 54 (54.0)                    | 112 (71.8) <sup>bc</sup>        |         |
| Insufficiency                                  | 52 (52.0)             | 36 (36.0)                    | 36 (23.1) <sup>bc</sup>         |         |
| Sufficiency                                    | 20 (20.0)             | 10 (10.0)                    | 8 (5.1) <sup>bc</sup>           |         |
| P-IL-6 (pg/ml)                                 | 14.1 $\pm$ 4.4        | 21.4 $\pm$ 8.3               | 48.4 $\pm$ 12.5 <sup>bd</sup>   | < 0.001 |
| P-IL-10 (ng/L)                                 | 4.6 $\pm$ 1.1         | 4.0 $\pm$ 1.3                | 3.5 $\pm$ 1.5                   | 0.105   |
| T-IL-6   | –                     | –                            | 3.58 (1.87, 6.25)               | –       |
| T-IL-10  | –                     | –                            | 0.59 (0.14, 1.26)               | –       |
| T-VDR  | –                     | –                            | 2.68 (0.65, 5.26)               | –       |

Data are presented mean  $\pm$  standard deviations or numbers (%) or median with IQR; Differences among three groups analyzed using one-way analysis of variance or  $\chi^2$  test, and least-significant difference (LSD) analysis was used for comparison between the two groups. versus NC group, <sup>a</sup> $P < 0.05$ , <sup>b</sup> $P < 0.01$ ; versus T2DM group, <sup>c</sup> $P < 0.05$ , <sup>d</sup> $P < 0.01$

NC normal control group, T2DM type 2 diabetes group, DFU diabetic foot ulcer group, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, TG triacylglycerol, TCH total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, PTH parathyroid hormone, eGFR estimated glomerular filtration rate, TcPO2 transcutaneous oxygen pressure, ABI ankle brachial index, CRP C-reactive protein, WBC white blood cell, ESR erythrocyte sedimentation rate, 25(OH)VD 25-hydroxyvitamin D, Vit D vitamin D, IL interleukin, P-IL-6 IL-6 level in peripheral blood, P-IL-10 IL-10 level in peripheral blood, T-IL-6 IL-6 mRNA expression in wound margin tissue, T-IL-10 IL-10 mRNA expression in wound margin tissue, T-VDR vitamin D receptor mRNA expression in wound margin tissue



**Table 2** Comparisons in clinical parameters between NDFO group and DFO group [n (%), ( $\pm$  s), M (P25, P75)]

| Variable                                   | NDFO group<br>(n = 72) | DFO group<br>(n = 84) | P value |
|--|------------------------|-----------------------|---------|
| Sex (male/female)                          | 72(42/30)              | 84(46/38)             | 0.654   |
| Age (year)                                 | 55.2 $\pm$ 11.6        | 55.8 $\pm$ 10.9       | 0.451   |
| Duration of diabetes (year)                | 10.8 $\pm$ 5.7         | 13.9 $\pm$ 6.8        | 0.014   |
| Duration of ulcers (week)                  | 5.1 (4.0, 9.3)         | 6.8 (4.8, 16.2)       | 0.003   |
| Area of DFU (cm <sup>2</sup> )             | 11.5 $\pm$ 4.3         | 10.7 $\pm$ 3.9        | 0.271   |
| Smoking habits                             | 38 (52.8)              | 42 (50.0)             | 0.729   |
| Alcohol consumption                        | 23 (31.9)              | 20 (23.8)             | 0.854   |
| Mean sunshine time per day (h)             | 3.2 (1.2, 5.8)         | 2.1 (1.1, 4.9)        | 0.025   |
| Winter enrollment                          | 30 (41.7)              | 39 (46.4)             | 0.551   |
| Wagner grade                               |                        |                       | < 0.001 |
| II   | 20 (27.8)              | 0 (0.00)              |         |
| III  | 47 (65.3)              | 61 (72.6)             |         |
| IV   | 5 (6.9)                | 23 (27.4)             |         |
| Severity of infection                      |                        |                       | < 0.001 |
| Mild                                       | 20 (27.8)              | 0 (0.00)              |         |
| Moderate                                   | 40 (55.6)              | 54 (64.3)             |         |
| Severe                                     | 12 (6.6)               | 30 (35.7)             |         |
| Recurrent DFU                              | 17 (23.6)              | 34 (40.5)             | 0.033   |
| Detection rate of drug -resistant bacteria | 17 (23.6)              | 34 (40.5)             | 0.025   |
| SBP (mm Hg)                                | 121 $\pm$ 13           | 125 $\pm$ 15          | 0.487   |
| DBP (mm Hg)                                | 81 $\pm$ 14            | 83 $\pm$ 15           | 0.679   |
| FPG (mmol/L)                               | 11.2 $\pm$ 2.5         | 12.8 $\pm$ 2.8        | 0.032   |
| HbA1c(%)                                   | 8.7 $\pm$ 1.5          | 9.5 $\pm$ 1.8         | 0.024   |
| TG (mmol/L)                                | 1.8 $\pm$ 0.8          | 2.4 $\pm$ 0.9         | 0.103   |
| TCH (mmol/L)                               | 4.7 $\pm$ 0.8          | 4.5 $\pm$ 0.7         | 0.594   |
| LDL-C (mmol/L)                             | 2.7 $\pm$ 0.5          | 2.9 $\pm$ 0.6         | 0.626   |
| HDL-C (mmol/L)                             | 1.0 $\pm$ 0.2          | 0.9 $\pm$ 0.3         | 0.753   |
| PTH (pg/mL)                                | 16.4 (9.7, 28.6)       | 18.1 (10.9, 39.2)     | 0.102   |
| Serum ionic calcium (mmol/L)               | 0.85 $\pm$ 0.15        | 0.87 $\pm$ 0.17       | 0.285   |
| eGFR (ml/min/1.73m <sup>2</sup> )          | 83.7 $\pm$ 11.9        | 71.5 $\pm$ 12.6       | 0.042   |
| ALB (g/L)                                  | 40.7 $\pm$ 8.9         | 35.7 $\pm$ 6.5        | 0.038   |
| Hb (g /L)                                  | 122.8 $\pm$ 9.3        | 104.8 $\pm$ 8.6       | 0.046   |
| TcPO2 (mm Hg)                              | 52.8 $\pm$ 8.5         | 39.1 $\pm$ 10.1       | 0.013   |
| ABI  | 0.82 $\pm$ 0.21        | 0.65 $\pm$ 0.14       | 0.026   |
| CRP ( mg/dL)                               | 31.7 $\pm$ 13.7        | 62.2 $\pm$ 18.5       | < 0.001 |
| WBC ( $\times 10^9$ )                      | 10.2 $\pm$ 3.6         | 12.9 $\pm$ 3.8        | 0.002   |
| ESR (mm/h)                                 | 36.7 $\pm$ 12.8        | 67.9 $\pm$ 17.2       | < 0.001 |
| 25(OH)VD (ng/mL)                           | 12.8 (6.9, 22.1)       | 9.2 (5.2, 20.5)       | 0.006   |
| VitD status                                |                        |                       | 0.007   |
| Deficiency                                 | 43 (59.7)              | 69 (82.1)             |         |
| Insufficiency                              | 23 (31.9)              | 13 (15.5)             |         |
| Sufficiency                                | 6 (8.4)                | 2 (2.4)               |         |

**Table 2** (continued)

| Variable       | NDFO group<br>(n = 72) | DFO group<br>(n = 84) | P value |
|----------------|------------------------|-----------------------|---------|
| P-IL-6 (pg/ml) | 39.2 ± 12.8            | 51.7 ± 14.5           | 0.009   |
| P-IL-10 (ng/L) | 4.7 ± 1.6              | 3.1 ± 1.2             | 0.036   |
| T-IL-6         | 2.93 (1.54, 4.82)      | 3.82 (2.07, 6.23)     | 0.013   |
| T-IL-10        | 0.72 (0.31, 1.32)      | 0.48 (0.12, 0.95)     | 0.036   |
| T-VDR          | 3.11 (1.36, 5.11)      | 1.96 (0.61–3.97)      | 0.004   |

Data are presented mean ± standard deviations or numbers (%) or median with IQR; Differences between two groups analyzed using t test or nonparametric test (Mann Whitney U)

DFU diabetic foot ulcer, NDFO diabetic foot ulcer without osteomyelitis, DFO diabetic foot osteomyelitis, SBP systolic blood pressure, DBP:diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, TG:triacylglycerol, TCH:total cholesterol, LDL-C:low-density lipoprotein cholesterol, HDL-C:high-density lipoprotein cholesterol, PTH parathyroid hormone, eGFR estimated glomerular filtration rate, ALB serum albumin, Hb haemoglobin, TcPO2 transcutaneous oxygen pressure, ABI ankle brachial index, CRP C-reactive protein, WBC white blood cell, ESR erythrocyte sedimentation rate; 25(OH)VD 25-hydroxyvitamin D, Vit D Vitamin D, IL interleukin, P-IL-6 IL-6 level in peripheral blood, P-IL-10 IL-10 level in peripheral blood, T-IL-6 IL-6 mRNA expression in wound margin tissue, T-IL-10 IL-10 mRNA expression in wound margin tissue, T-VDR vitamin D receptor mRNA expression in wound margin tissue

**Table 3** Relationship between serum 25(OH)VD levels and the clinical features of DFU patients [(± s), n (%)]

|   | High level group<br>(n = 58) | Low level group<br>(n = 98) | P value |
|---|------------------------------|-----------------------------|---------|
| Age (y)                                   | 54.8 ± 10.8                  | 56.2 ± 11.3                 | 0.426   |
| Sex                                       |                              |                             | 0.273   |
| Male                                      | 36 (62.1)                    | 52 (53.1)                   |         |
| Female                                    | 22 (37.9)                    | 46 (46.9)                   |         |
| Ulcer area (cm <sup>2</sup> )             |                              |                             | 0.856   |
| ≤ 5                                       | 8 (13.8)                     | 16 (16.3)                   |         |
| 5 ~ 10                                    | 32 (55.2)                    | 55 (56.1)                   |         |
| > 10                                      | 18 (31.0)                    | 27 (27.6)                   |         |
| Ulcer duration (week)                     |                              |                             | 0.043   |
| ≤ 6                                       | 10 (17.2)                    | 11 (11.2)                   |         |
| 6 ~ 10                                    | 33 (56.9)                    | 42 (42.9)                   |         |
| > 10                                      | 15 (25.9)                    | 45 (45.9)                   |         |
| Wagner grade                              |                              |                             | 0.005   |
| II  | 14 (24.1)                    | 6 (6.1)                     |         |
| III                                       | 35 (60.3)                    | 73 (74.5)                   |         |
| IV  | 9 (15.6)                     | 19 (19.4)                   |         |
| Severity of infection                     |                              |                             | 0.003   |
| Mild                                      | 14 (24.1)                    | 6 (6.1)                     |         |
| Moderate                                  | 28 (48.3)                    | 66 (67.3)                   |         |
| Severe                                    | 16 (27.6)                    | 26 (26.6)                   |         |
| Recurrent DFU                             | 12 (20.7)                    | 39 (39.8)                   | 0.014   |
| Detection rate of drug resistant bacteria | 13 (22.4)                    | 38 (38.8)                   | 0.035   |
| Outcome of ulcer after 8 weeks            |                              |                             | 0.031   |
| Healing                                   | 37 (63.8)                    | 45 (45.9)                   |         |
| Non-healing                               | 21 (36.2)                    | 53 (54.1)                   |         |
| Amputation rate (%)                       |                              |                             | 0.035   |
| Amputation                                | 9 (15.5)                     | 30 (30.6)                   |         |
| Non-amputation                            | 49 (84.5)                    | 68 (69.4)                   |         |

Data are presented mean ± standard deviations or numbers (%); Differences between two groups analyzed using t test or  $\chi^2$  test. The cut-off point of serum vitamin D level for grouping was 10.3 ng/mL

DFU diabetic foot ulcer, 25(OH)VD 25-hydroxyvitamin D



**Table 4** Relationship between the levels of T-VDR expression and the clinical features of DFU patients [(±s), n (%)]

|   | High expression group (n = 53) | Low expression group (n = 103) | P value |
|---|--------------------------------|--------------------------------|---------|
| Age (y)                                   | 55.1 ± 10.8                    | 55.8 ± 11.3                    | 0.613   |
| Sex                                       |                                |                                | 0.162   |
| Male                                      | 34 (64.2)                      | 54 (52.4)                      |         |
| Female                                    | 19 (35.8)                      | 49 (47.6)                      |         |
| Ulcer area (cm <sup>2</sup> )             |                                |                                | 0.787   |
| ≤ 5                                       | 7 (13.2)                       | 17 (16.5)                      |         |
| 5~10                                      | 30 (56.6)                      | 57 (55.4)                      |         |
| > 10                                      | 16 (30.2)                      | 29 (28.1)                      |         |
| Ulcer duration (week)                     |                                |                                | 0.014   |
| ≤ 6                                       | 9 (17.0)                       | 12 (11.7)                      |         |
| 6~10                                      | 32 (60.4)                      | 43 (41.7)                      |         |
| > 10                                      | 12 (22.6)                      | 48 (46.6)                      |         |
| Wagner grade                              |                                |                                | 0.030   |
| II  | 12 (22.6)                      | 8 (7.7)                        |         |
| III                                       | 32 (60.3)                      | 76 (73.9)                      |         |
| IV  | 9 (7.1)                        | 19 (18.4)                      |         |
| Severity of infection                     |                                |                                | 0.021   |
| Mild                                      | 12 (22.6)                      | 8 (7.8)                        |         |
| Moderate                                  | 26 (49.1)                      | 68 (66.0)                      |         |
| Severe                                    | 15 (28.3)                      | 27 (26.2)                      |         |
| Recurrent DFU                             | 11 (20.8)                      | 40 (38.8)                      | 0.023   |
| Detection rate of drug resistant bacteria | 10 (18.9)                      | 41 (39.8)                      | 0.012   |
| Outcome of ulcer after 8 weeks            |                                |                                | 0.016   |
| Healing                                   | 35 (66.0)                      | 47 (45.6)                      |         |
| Non-healing                               | 18 (34.0)                      | 56 (54.4)                      |         |
| Amputation rate (%)                       |                                |                                | 0.040   |
| Amputation                                | 8 (15.1)                       | 31 (30.1)                      |         |
| Non-amputation                            | 45 (84.9)                      | 72 (69.9)                      |         |

Data are presented mean ± standard deviations or numbers (%); Differences between two groups analyzed using t test or  $\chi^2$  test. The cut-off point of vitamin D receptor expression level for grouping was 2.68

DFU diabetic foot ulcer

25(OH)VD and T-VDR expression and other clinical features of foot ulcer (Tables 3, 4). Additionally, Research data also showed the relationship between the levels of T-VDR expression and the clinical features of DFO is similar to that found in foot ulcer (Table 5).

#### Correlation between serum 25(OH)VD levels and other clinical parameters

In NC group and T2DM group, serum 25(OH)VD levels were positively correlated with mean sunshine duration per day ( $P < 0.05$ ). Additionally, in the T2DM group, serum 25(OH)VD levels were positively correlated with HDL-C


**Table 5** Relationship between the levels of T-VDR expression and the clinical features of DFO patients [(±s), n (%)]

|   | High expression group (n = 32) | Low expression group (n = 52) | P value |
|---|--------------------------------|-------------------------------|---------|
| Age (y)                                   | 55.6 ± 10.5                    | 56.4 ± 11.1                   | 0.482   |
| Sex                                       |                                |                               | 0.830   |
| Male                                      | 18 (56.3)                      | 28 (53.8)                     |         |
| Female                                    | 14 (43.7)                      | 24 (46.2)                     |         |
| Ulcer area (cm <sup>2</sup> )             |                                |                               | 0.786   |
| ≤ 5                                       | 3 (9.4)                        | 7 (13.5)                      |         |
| 5~10                                      | 18 (56.3)                      | 30 (57.7)                     |         |
| > 10                                      | 11 (34.3)                      | 15 (28.8)                     |         |
| Ulcer duration (week)                     |                                |                               | 0.037   |
| ≤ 6                                       | 4 (12.5)                       | 5 (9.6)                       |         |
| 6~10                                      | 18 (56.3)                      | 16 (30.8)                     |         |
| > 10                                      | 10 (31.2)                      | 31 (59.6)                     |         |
| Wagner grade                              |                                |                               | 0.011   |
| II  | 0 (0.0)                        | 0 (0.0)                       |         |
| III                                       | 25 (75.0)                      | 25 (46.1)                     |         |
| IV  | 7 (18.7)                       | 27 (48.1)                     |         |
| Severity of infection                     |                                |                               | 0.041   |
| Mild                                      | 0 (0.0)                        | 0 (0.0)                       |         |
| Moderate                                  | 24 (75.0)                      | 27 (51.9)                     |         |
| Severe                                    | 8 (25.0)                       | 25 (48.1)                     |         |
| Recurrent DFU                             | 8 (25.0)                       | 26 (50.0)                     | 0.023   |
| Detection rate of drug resistant bacteria | 7 (21.9)                       | 27 (51.9)                     | 0.006   |
| Outcome of ulcer after 8 weeks            |                                |                               | 0.021   |
| Healing                                   | 20 (62.5)                      | 19 (36.5)                     |         |
| Non-healing                               | 12 (37.5)                      | 33 (63.5)                     |         |
| Amputation rate (%)                       |                                |                               | 0.039   |
| Amputation                                | 5 (15.6)                       | 19 (36.5)                     |         |
| Non-amputation                            | 27 (84.4)                      | 33 (63.5)                     |         |

Data are presented mean ± standard deviations or numbers (%); Differences between two groups analyzed using t test or  $\chi^2$  test. The cut-off point of vitamin D receptor expression level for grouping was 2.68

DFU diabetic foot ulcer, DFO diabetic foot osteomyelitis

and eGFR levels ( $P < 0.05$ ), and negatively correlated with FPG, HbA1c levels, and season (winter) ( $P < 0.05$ ). There was no significant correlation between serum 25(OH)VD levels and other clinical parameters in T2DM group and NC group ( $P > 0.05$ ) (Additional file 1: Fig. S1). As for the NDFO group and the DFO group, serum 25(OH)VD levels were positively correlated with mean sunshine duration per day, ulcer time, Wagner grade, infection severity, recurrence of foot ulcer, HDL-C, P-IL-10, T-IL-10, and T-VDR expression levels ( $P < 0.05$ ). However, serum 25(OH)VD levels showed a negative correlation with season (winter), FPG, HbA1c, CRP, P-IL-6, and T-IL-6 expression levels



**Fig. 2** The correlations between serum 25(OH)VD levels and other clinical parameters in NDFO and DFO group (*r*). Pearson correlation analysis showed that serum 25(OH)VD levels were positively correlated with mean sunshine duration per day, ulcer time, Wagner grade, infection severity, recurrence of foot ulcer, HDL-C, P-IL-10, T-IL-10, and T-VDR levels in NDFO group and DFO group, ( $P < 0.05$ ), but negatively correlation with season (winter), FPG, HbA1c, CRP, P-IL-6, and T-IL-6 levels ( $P < 0.05$ ). Serum 25(OH)VD levels were also positively correlated with TcPO2 and ABI in the DFO group ( $P < 0.05$ ), and negatively correlated with WBC, ESR ( $P < 0.05$ ). *NDFO* diabetic foot ulcer without osteomyelitis, *DFO* diabetic foot osteomyelitis, *DFU* diabetic foot ulcer, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *FPG* fasting plasma glucose, *HbA1c* glycated hemoglobin A1c, *TG* triacylglycerol, *TCH* total cholesterol, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* high-density lipoprotein cholesterol, *PTH* parathyroid hormone, *eGFR* estimated glomerular filtration rate, *ALB* serum albumin, *Hb* haemoglobin, *TcPO2* transcutaneous oxygen pressure, *ABI* ankle brachial index, *CRP* C-reactive protein, *WBC* white blood cell, *ESR* erythrocyte sedimentation rate, *IL* interleukin, *T-IL-6* IL-6 mRNA expression in wound margin tissue, *T-IL-10* IL-10 mRNA expression in wound margin tissue, *T-VDR* vitamin D receptor mRNA expression in wound margin tissue, *IL* interleukin, *P-IL-6* IL-6 level in peripheral blood, *P-IL-10* IL-10 level in peripheral blood, *T-IL-6* IL-6 mRNA expression in wound margin tissue, *T-IL-10* IL-10 mRNA expression in wound margin tissue, *T-VDR* vitamin D receptor mRNA expression in wound margin tissue

( $P < 0.05$ ). In addition, in the DFO group, serum 25(OH)VD levels were also positively correlated with TcPO2 and ABI ( $P < 0.05$ ), and negatively correlated with WBC, ESR ( $P < 0.05$ ). No significant correlation between serum

25(OH)VD levels and other clinical parameters was observed in the NDFO group and the DFO group ( $P > 0.05$ ) (Fig. 2).

**Table 6** The multivariate logistic regression analysis of risk factors of diabetic foot ulcer

| Variable                          | $\beta$ | SE   | Wald | OR   | 95% CI       | P value |
|-----------------------------------|---------|------|------|------|--------------|---------|
| Duration of diabetes (y)          | 0.47    | 0.29 | 9.56 | 4.13 | 1.64 ~ 12.15 | < 0.001 |
| HbA1c (%)                         | 0.34    | 0.17 | 3.51 | 1.26 | 1.13 ~ 6.77  | 0.031   |
| eGFR (ml/min/1.73m <sup>2</sup> ) | 0.26    | 0.14 | 2.97 | 1.13 | 1.04 ~ 6.23  | 0.046   |
| TcPO <sub>2</sub> (mmHg)          | 0.41    | 0.27 | 4.13 | 1.69 | 1.18 ~ 9.84  | 0.019   |
| CRP (mg/L)                        | 0.45    | 0.23 | 3.14 | 1.22 | 1.09 ~ 7.96  | 0.025   |
| 25 (OH) VD (ng/ml)                | 0.62    | 0.34 | 5.43 | 2.42 | 1.37 ~ 10.88 | 0.008   |

Multivariate unconditional logistic regression analysis adjusted for sex, age, duration of diabetes, frequent smoking, long term drinking, mean sunshine time per day, SBP, DBP, FPG, HbA1c, TG, TCH, LDL-C, HDL-C, eGFR, ALB, Hb, TcPO<sub>2</sub>, ABI, CRP, WBC, ESR, P-IL-6, P-IL-10, serum 25 (OH) VD

SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, TG triacylglycerol, TCH total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, eGFR Estimated glomerular filtration rate, ALB serum albumin, Hb hemoglobin, TcPO<sub>2</sub> transcutaneous oxygen pressure, ABI ankle brachial index, CRP C-reactive protein, WBC white blood cell, ESR erythrocyte sedimentation rate, P-IL-6 IL-6 level in peripheral blood, P-IL-10 IL-10 level in peripheral blood, 25(OH)VD 25-hydroxyvitamin D

### Risk factor analysis for diabetes foot ulcer and diabetes foot osteomyelitis

In diabetic patients, multivariate unconditional logistic regression was performed with DFU as the dependent variable and sex, age, duration of diabetes, regular smoking, long-term alcohol consumption, mean sunshine duration per day in the recent 3 months, SBP, DBP, FPG, HbA1c, TG, TCH, LDL-C, HDL-C, eGFR, ALB, Hb, TcPO<sub>2</sub>, ABI, CRP, WBC, ESR, serum 25(OH)VD level, P-IL-6 level and P-IL-10 level as independent variables, respectively. The results showed that the duration of diabetes, HbA1c, eGFR, TcPO<sub>2</sub>, CRP, and low serum 25(OH)VD level was independent risk factors for DFU (Table 6). Also, in the DFU patients, multivariate unconditional logistic regression was performed with DFO as the dependent variable and sex, age, duration of diabetes, duration of foot ulcer, area of foot ulcer, regular smoking, long-term drinking, mean sunshine duration per day in the recent 3 months, Wagner grade, the severity

of wound infection, detection of drug-resistant bacteria, SBP, DBP, FPG, HbA1c, TG, TCH, LDL-C, HDL-C, eGFR, ALB, Hb, TcPO<sub>2</sub>, ABI, CRP, WBC, ESR, serum 25(OH)VD level, P-IL-6 level, P-IL-10 level, T-IL-6, T-IL-10, and T-VDR expression levels as independent variables. The final analysis indicated that independent risk factors for DFO included the duration of foot ulcer, the severity of infection, HbA1c, ABI, WBC, ESR, low serum 25(OH)VD level, and low level of T-VDR expression (Table 7).

### Mark verification


To further investigate the potential value of 25(OH)VD in the diagnosis of DFU, the levels of serum 25(OH)VD were evaluated in 256 independent peripheral blood samples (including 100 samples of patients with T2DM and 156 with DFU). The sensitivity and specificity of serum 25(OH)VD in the diagnosis of DFU were evaluated using the ROC curve. The results showed that the area under

**Table 7** The multivariate logistic regression analysis of risk factors of diabetic foot osteomyelitis

| Variable               | $\beta$ | SE   | Wald | OR   | 95% CI       | P value |
|------------------------|---------|------|------|------|--------------|---------|
| Duration of ulcers (w) | 0.69    | 0.35 | 9.22 | 4.81 | 1.21 ~ 11.63 | < 0.001 |
| Severity of infection  | 0.52    | 0.29 | 5.83 | 2.07 | 1.09 ~ 10.34 | 0.012   |
| HbA1c (%)              | 0.41    | 0.23 | 6.03 | 2.35 | 1.24 ~ 9.26  | 0.009   |
| ABI                    | 0.38    | 0.19 | 3.59 | 1.46 | 1.12 ~ 7.49  | 0.027   |
| WBC ( $\times 10^9$ )  | 0.21    | 0.11 | 2.87 | 1.19 | 1.04 ~ 6.18  | 0.041   |
| ESR (mm/h)             | 0.46    | 0.25 | 4.96 | 1.87 | 1.13 ~ 9.15  | 0.018   |
| 25 (OH) VD (ng/ml)     | 0.58    | 0.26 | 7.15 | 3.05 | 1.07 ~ 12.53 | 0.001   |
| T-VDR                  | 0.49    | 0.17 | 5.12 | 2.83 | 1.15 ~ 9.97  | 0.004   |

Multivariate unconditional logistic regression analysis adjusted for sex, age, duration of diabetes, duration of ulcers, frequent smoking, long term drinking, mean sunshine time per day, Wagner grade, severity of infection, detection rate of drug resistant bacteria, SBP, DBP, FPG, HbA1c, TG, TCH, LDL-C, HDL-C, eGFR, ALB, Hb, TcPO<sub>2</sub>, ABI, CRP, WBC, ESR, P-IL-6, P-IL-10, serum 25 (OH)VD

SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, TG triacylglycerol, TCH total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, eGFR Estimated glomerular filtration rate, ALB serum albumin, Hb hemoglobin, TcPO<sub>2</sub> transcutaneous oxygen pressure, ABI ankle brachial index, CRP C-reactive protein, WBC white blood cell, ESR erythrocyte sedimentation rate, P-IL-6 IL-6 level in peripheral blood, P-IL-10 IL-10 level in peripheral blood, 25(OH)VD 25-hydroxyvitamin D, T-VDR vitamin D receptor mRNA expression in wound margin tissue



**Fig. 3** The biomarker potential of serum 25(OH)VD for DFU and DFO and that of T-VDR for DFO. **A** Serum 25(OH)VD distinguished DFU patients from controls with area under curve (AUC) of 0.821 (95% CI: 0.754–0.886,  $P < 0.001$ ). **B** Serum 25(OH)VD distinguished DFO patients from DFU patients (AUC: 0.786; 95%CI: 0.643–0.867,  $P < 0.001$ ). **C** T-VDR distinguished DFO patients from DFU patients (AUC: 0.703; 95%CI: 0.618–0.853,  $P < 0.001$ ). 25(OH)VD 25-hydroxyvitamin D, DFU diabetic foot ulcer, DFO diabetic foot osteomyelitis, T-VDR Vitamin D receptor mRNA expression in wound margin tissue. [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

the ROC curve (AUC) of serum 25(OH)VD in the diagnosis of DFU was 0.821 (95% confidence interval [CI], 0.754–0.886,  $P < 0.001$ ), the optimal cutoff point of serum 25(OH)VD was 12.5 ng/mL, the sensitivity was 96.35%, and the specificity was 95.82% (Fig. 3A). In order to further explore the potential value of serum 25(OH)VD and T-VDR to establish the diagnosis of DFO, the levels of serum 25(OH)VD and T-VDR expression were evaluated in 156 cases peripheral blood samples and wound margin tissue samples in independent groups; these samples included samples of 72 patients with DFU without osteomyelitis and of 84 patients with DFO. The sensitivity and specificity of levels of serum 25(OH)VD and T-VDR expression in the diagnosis of DFO were evaluated using the ROC curve. The results showed that the AUC of serum 25(OH)VD level in the diagnosis of DFO was 0.786 (95%CI, 0.643–0.867,  $P < 0.001$ ), the optimal cut-off point of serum 25(OH)VD level was 8.6 ng/mL, the sensitivity was 94.61%, and the specificity was 96.13% (Fig. 3B). The AUC of T-VDR expression level in diagnosing DFO was 0.703 (95%CI, 0.618–0.853,  $P < 0.001$ ), the optimal cut-off point of T-VDR expression level was 1.14, the sensitivity was 94.23%, and the specificity was 95.82% (Fig. 3C).

## Discussion

In the present study, T2DM patients showed lower levels of serum 25(OH)VD and higher proportions of vitamin D deficiency and insufficiency than individuals with normal glucose tolerance. In addition, the levels of serum 25(OH)VD in DFU patients were also significantly lower than that of diabetes patients without DFU. But it has to be said on condition that the foot ulcer infection

progresses to diabetic foot osteomyelitis, the levels of serum 25(OH)VD and T-VDR expression will decrease sharply, and the proportion of vitamin D deficiency will also increase significantly. Multivariate logistic regression analysis revealed that decreased serum 25(OH)VD level was an independent risk factor for DFU and DFO, and decreased T-VDR expression level was an independent risk factor for DFO. Further analysis showed that the levels of serum 25(OH)VD and T-VDR expression of patients with T2DM could be used as markers to predict DFU and DFO, and were closely related to the healing rate of foot ulcer and amputation rate. DFU with low serum 25(OH)VD level and low T-VDR expression level had a lower healing rate and higher risk of amputation, indicating that vitamin D deficiency and decreased VDR expression level are not only strong risk factors for the onset of DFU and DFO but also as potential biomarkers for the prognosis of DFU and DFO. To the best of our knowledge, this is the first systematic study on the relationship between changes in serum 25(OH)VD level and T-VDR expression level with the onset and treatment outcomes of DFU and DFO in patients with T2DM.

A prospective cohort study from Australia reported that 55.7% of hospitalized patients with DFU presented with vitamin D deficiency [18]. According to a retrospective study in the United States, 78% of patients with DFU undergoing foot and ankle surgery showed vitamin D deficiency or insufficiency [19]. In addition, a single-center retrospective study of inpatient DFU patients from China showed vitamin D deficiency in 86.8% of patients with DFU [20]. The results of the present study demonstrated that vitamin D deficiency was 71.8% in DFU and 82.1% in DFO. Additionally, vitamin D deficiency

and insufficiency became more pronounced as DFU progressed, with a Wagner grade of 4 and the presence of DFU with severe infection reaching 100%. Therefore, through these results, it is evident that vitamin D deficiency and insufficiency are prevalent in DFU and may be associated with the severity of DFU. Some studies reported that the increase of Wagner grade resulted in a reduction in the levels of 25(OH)VD in the peripheral blood of patients with DFU [20], which supported our findings.

In the present study, we noted that the levels of serum 25(OH)VD were significantly lower in patients with T2DM than in individuals in the NC group. Correlation analysis showed that serum 25(OH)VD levels were negatively correlated with FPG and HbA1c, and positively correlated with HDL-C, both in T2DM alone and in T2DM with foot ulcers, which suggested that the levels of vitamin D in patients with T2DM were intrinsically correlated with glucose and lipid metabolism, which were consistent with previous findings [21, 22]. Furthermore, the outcomes of the present study showed that the levels of serum 25(OH)VD were negatively correlated with the duration of foot ulcers, Wagner grade of foot ulcers, the severity of wound infection (including IDSA grade, inflammatory indicators including CRP, WBC, ESR, and IL-6 levels, ect.), the recurrence rate of foot ulcers, and detection rate of drug-resistant bacteria in wounds in patients with DFU. However, the levels of serum 25(OH)VD were positively correlated with the levels of anti-inflammatory factor IL-10. Previous studies have confirmed that drug-resistant bacteria are risk factors for the recurrence of DFU [23, 24]. Therefore, the results of the current study suggested that the levels of serum 25(OH)VD in patients with DFU is related to the severity of DFU, the severity and complexity of wound infection, and the risk of foot ulcer recurrence. A study has found [25] that vitamin D can promote the differentiation of dendritic cells and regulatory T cells by binding to VDR, and reduce the Th17 response of T helper cells and the secretion of inflammatory cytokines, in order to play an anti-inflammatory role. In addition, vitamin D can enhance the expression of antimicrobial peptides in a variety of cells, which can help eliminate microorganisms, inhibit proinflammatory responses, and enhance anti-inflammatory responses [10]. These observations are consistent with the conclusions presented in the current study. Moreover, in the NC, T2DM, and DFU groups of the present study, we observed that the levels of serum 25(OH)VD were associated with the mean sunshine duration and season, and the serum 25(OH)VD levels were relatively lower in the subjects with short sunshine time and winter. In most areas of China with relatively less sunshine in winter and spring, the average levels of

serum 25(OH)VD were reportedly low [26]. A study from Germany suggested that sunshine duration was closely related to the levels of serum 25(OH)VD; additionally, a shorter sunshine duration was associated with lower serum 25(OH)VD levels [27]. Specifically, in this study, the sunshine duration in the DFU group was lower than that in the NC group and T2DM group, which may be correlated to the inconvenience of activity and the reduction of outdoor exercise attributable to DFU.

Notably, in this study, the duration of foot ulcer in the DFU group was at least 4 weeks, which indicated the presence of chronic refractory wound. The clinical features include a long duration of diabetes and poor long-term blood glucose control in combination with different degrees of chronic kidney disease, abnormal lipid metabolism, peripheral vascular disease, and infectious inflammation. Wagner classification was predominantly grades 3–4. Multivariate regression analysis showed that duration of diabetes, HbA1c, TcPO<sub>2</sub>, CRP, and eGFR were independent factors influencing the occurrence of foot ulcers, which were consistent with previous findings [28, 29]. Further analysis confirmed that compared with the T2DM group, serum 25(OH)VD levels in the DFU group were significantly lower, and the proportion of vitamin D deficiency was higher; the serum 25(OH)VD levels were negatively correlated with the duration of ulcer, and positively correlated with the ulcer healing rate after 8 weeks of treatment as well amputation rate. Multivariate regression analysis showed that low levels of serum 25(OH)VD were an independent risk factor for foot ulcers. It is suggested that 25(OH)VD may be involved in the occurrence of diabetic foot ulcers and can be used as a marker for the prognosis of DFU. Multiple studies have reported that vitamin D deficiency is significantly associated with a high prevalence of DFU [30, 31]. A meta-analysis reported that vitamin D levels were significantly reduced in patients with DFU, and severe vitamin D deficiency was significantly associated with an increased risk of DFU [6]. The basic elements of diabetic foot are diabetic lower extremity arterial disease and peripheral neuropathy. Low levels of serum 25(OH)VD in patients with T2DM are closely related to the occurrence of arterial lesions in the lower extremity [32]. Investigation has shown that the incidence of vitamin D deficiency in patients with T2DM with peripheral neuropathy in China is 80%, and vitamin D deficiency is an independent risk factor for diabetic peripheral neuropathy [33]. These results support our findings.

At present, it is generally believed that the adverse effects of the high glucose environment in the body, the obvious changes in the skin microenvironment, the low immune function, the reduced antibacterial ability of the wound, the damaged function of keratinocytes



and fibroblasts, and the insufficient angiogenesis of the wound are all important influencing factors for the difficulty of DFU healing [34]. However, the physiological relationship between the levels of vitamin D and VDR expression and wound healing in diabetes have not been fully understood. Gonzalez-Curiel et al. reported that 1,25(OH)2D3 can upregulate the expression of DEFBA4 and CAMP genes in primary keratinocytes from DFU, increase the production of HBD-2 and LL-37 in cell-culture supernatant, and improve the migration ability and antibacterial activity of keratinocytes, thus promoting wound healing [35]. Xiong et al. found that 1,25(OH)2D3 can inhibit excessive autophagy and oxidative stress in vascular endothelial cells caused by advanced glycation end products (AGEs) through the PI3K/Akt pathway, thereby promoting angiogenesis in a high-glucose environment [36], which is conducive to wound healing. Animal experiments have demonstrated that vitamin D can improve wound healing in diabetic mice by inhibiting the expression of inflammatory genes such as IL-6 and IL-1 $\beta$  mediated by NF- $\kappa$ B [37] and inhibiting endoplasmic reticulum stress [38]. In vitro studies have confirmed that 1,25(OH)2D3 can promote the transformation of M1 macrophages to M2 macrophages induced by high glucose through the VDR-PPAR $\gamma$  signaling pathway, and enhance the bactericidal activity of macrophages against *Pseudomonas aeruginosa* [39]. Recent studies have confirmed that 1,25(OH)2D3 can upregulate the complement receptor immunoglobulin (CRIg) in macrophages—which play an important role in innate immunity—and enhance the phagocytosis of macrophages against *Staphylococcus aureus* and *Candida albicans* [40]. In the wound infection model, topical application of 1,25(OH)2D3 to the skin of CAMP transgenic mice can induce CAMP expression and increase the killing effect of *Staphylococcus aureus* [41]. Clinical studies have shown a significant association between the functional variation of the VDR gene FokI and DFU and oxidative stress. Patients with T2DM carrying the T allele of FokI polymorphism have increased levels of oxidative stress and a higher risk of foot ulcers [42]. Although a series of studies have explored the possible mechanism of vitamin D and VDR involvement in the occurrence and healing of diabetic wounds from different aspects, additional studies are warranted to further clarify in the future.

Further analysis found that compared with simple foot ulcers, patients with foot ulcers combined with osteomyelitis had a longer duration of diabetes and foot ulcers, higher Wagner grade of foot ulcers, poorer glycaemic control status, as well as worse limb blood supply status, more severe degree of infection, more severe infection along with higher proportion of drug-resistant infection.

Multivariate regression analysis showed that the duration of foot ulcer, the severity of wound infection, HbA1c, ABI, WBC, and ESR were independent influencing factors for the occurrence of foot ulcer complicated with osteomyelitis, which was consistent with previous findings [28, 43]. More details, further analysis showed that the serum 25(OH)VD levels and T-VDR expression levels in the DFO group were further decreased compared with the NDFO group; the serum 25(OH)VD levels in patients with DFO were positively correlated with T-VDR expression levels; the levels of serum 25(OH)VD and T-VDR expression were negatively correlated with the amputation rate of foot ulcers with osteomyelitis. Multivariate regression analysis showed that low level of serum 25(OH)VD and VDR expression were independent risk factors for foot ulcer with osteomyelitis. Meanwhile, it suggested that 25(OH)VD and VDR might be involved in the occurrence of DFO and can be used as a marker for the risk of DFO amputation. A cross-sectional study from India showed that vitamin D deficiency was associated with poor prognosis in co-infected DFU, leading to osteomyelitis, amputation, and increased risk of death [9], thereby supporting our findings. DFO is mostly chronic osteomyelitis, which is caused by bone destruction and dead bone formation caused by infection. Therefore, the ability of infection clearance, osteoblast-mediated bone formation, and osteoclast-regulated bone resorption are crucial to the repair of bone injury, and can directly affect the clinical outcome of osteomyelitis. Shekhar C reported that the local application of vitamin D3 particles in open infectious wounds could increase the expression of antimicrobial peptides (cathelicidin) in wounds, enhance the antibacterial ability of wounds, promote bone growth, and restore bone mineral density [44]. A retrospective cohort study of patients with bone and joint infection showed that low level of serum 25(OH)VD could reduce the success rate of treatment for bone infection [45]. Li et al. found that 1,25(OH)2D3 could increase the expression of the anti-inflammatory factor IL-10 by reducing the expression of genes related to osteoclasts (c-Fos, NFATc1, CTSK, and TRAP) and pro-inflammatory factors (IL-6, IL-12p40, and TNF- $\alpha$ ), thereby reducing bone resorption in a mouse skull model infected with *Porphyromonas gingivalis* [46]. Studies have revealed that the binding of 1,25(OH)2D3 to VDR can inhibit the nuclear transmigration of NF- $\kappa$ B-P65, IL-8, IL-6, TNF $\alpha$ , and NR4A2 transcripts in human bone marrows derived mesenchymal stem cells, demonstrating the anti-MRSA infection effect of active vitamin D [47]. Jiang et al. demonstrated that both TaqI (rs731236) and FokI (rs2228570) polymorphisms of the VDR gene can increase the risk of chronic osteomyelitis in the Chinese population [48].

Although some studies have confirmed that vitamin D and VDR play a role in the pathogenesis of osteomyelitis, further studies are warranted to elucidate the mechanism of 25(OH)VD and VDR involved in the occurrence of DFO.

It turned out that the levels of 25(OH)VD in peripheral blood could be used as a biomarker for predicting and diagnosing mild cognitive impairment [49] and active Crohn's disease [50]. In addition, VDR expression can be used as a biomarker to predict sepsis mortality [51] and bone metastasis of breast cancer [52]. In the present study, we noted that serum 25(OH)VD level in patients with T2DM can be used as a potential biomarker for predicting DFU and DFO. In addition, the T-VDR expression was also found to be a potential biomarker for predicting DFO. What is more, we also discovered that the levels of serum 25(OH)VD and T-VDR expression were negatively correlated with the duration of DFU, the severity of foot ulcer, the recurrence rate of foot ulcer, the detection rate of drug-resistant bacteria in the wound and the amputation rate of simple foot ulcers or foot ulcers combined with osteomyelitis. On the contrary, it also represents positively correlated with the healing rate of simple foot ulcers or foot ulcers combined with osteomyelitis after 8 weeks of treatment. Therefore, the forementioned results illustrate the functionality of serum 25(OH)VD level and T-VDR expression for the diagnosis and prognosis of DFU and DFO. Nonetheless, further studies are needed to identify the reasons for the decreased levels of serum 25(OH)VD and T-VDR expression with DFU and DFO.

In conclusion, this study found that the decreased levels of serum 25(OH)VD and T-VDR expression of type 2 diabetes patients was closely associated with the occurrence, development and prognosis of DFU. Yet when it comes to the shortcomings of this study, the main shortcoming as follows: (1) it is a single-center study with a relatively small sample size, and selection bias. (2) There are differences in the duration of diabetes and blood glucose levels between the T2DM group and the DFU group, which may affect the expression profile of cytokines, and may affect the results of multivariate unconditional logistic regression as a confounding factor. Therefore, the results of this study need to be further confirmed. (3) The influence of lifestyle, diet, and other factors on serum 25(OH)VD level was not considered. (4) The causal relationship between 25(OH)VD, VDR, and the pathogenesis of DFU (including DFO) could not be clarified in the present study. In the future, more studies are needed to further explore the role of 25(OH)VD and VDR in DFU (including DFO) and to evaluate whether 25(OH)VD and VDR can become new therapeutic targets for DFU (including DFO).

## Abbreviations

|                   |  |
|-------------------|--|
| T2DM              | Type 2 diabetes mellitus                         |
| DFU               | Diabetic foot ulcer                              |
| DFO               | Diabetic foot osteomyelitis                      |
| VDR               | Vitamin D receptor                               |
| 25(OH)VD          | 25-Hydroxyvitamin D                              |
| ABI               | Ankle-brachial index                             |
| OGTT              | Oral glucose tolerance test                      |
| FPG               | Fasting plasma glucose                           |
| NPWT              | Negative pressure wound treatment                |
| MDT               | Multidisciplinary team                           |
| SBP               | Systolic blood pressure                          |
| DBP               | Diastolic blood pressure                         |
| IDSA              | Infectious Disease Society of America            |
| TcPO <sub>2</sub> | Transcutaneous oxygen pressure                   |
| HbA1c             | Glycosylated hemoglobin A1c                      |
| WBC               | White blood cell                                 |
| CRP               | C-reactive protein                               |
| ESR               | Erythrocyte sedimentation rate                   |
| PTH               | Parathyroid hormone                              |
| TCH               | Total cholesterol                                |
| TG                | Triglyceride                                     |
| HDL-C             | High-density lipoprotein cholesterol             |
| LDL-C             | Low-density lipoprotein cholesterol              |
| ALB               | Serum albumin                                    |
| Hb                | Hemoglobin                                       |
| IL-6              | Interleukin-6                                    |
| IL-10             | Interleukin-10                                   |
| eGFR              | Estimated glomerular filtration rate             |
| qRT-PCR           | Quantitative real-time polymerase chain reaction |
| T-VDR             | Vitamin D receptor mRNA in wound margin tissues  |
| T-IL-6            | Interleukin-6 mRNA in wound margin tissues       |
| T-IL-10           | Interleukin-10 mRNA in wound margin tissues      |
| ROC               | Receiver operating characteristic                |
| P-IL-10           | Interleukin-10 levels in peripheral blood        |
| P-IL-6            | Interleukin-6 levels in peripheral blood         |
| AGEs              | Advanced glycation end products                  |
| CRlg              | Complement receptor immunoglobulin               |

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13098-023-01002-3>.

**Additional file 1: Figure S1.** The correlations between serum 25(OH)VD levels and other clinical parameters in the NC and T2DM group (*r*). Pearson correlation analysis showed that serum 25(OH)VD levels were positively correlated with mean sunshine duration per day in NC group ( $P < 0.05$ ) and were positively correlated with mean sunshine duration per day, HDL-C and eGFR levels in T2DM group ( $P < 0.05$ ), but negatively correlated with FPG, HbA1c levels, and season (winter) ( $P < 0.05$ ). NC: normal control group; T2DM: type 2 diabetes group; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin A1c; TG: triacylglycerol; TCH: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; PTH: parathyroid hormone; eGFR: estimated glomerular filtration rate; ALB: serum albumin; Hb: haemoglobin; TcPO<sub>2</sub>: transcutaneous oxygen pressure; ABI: ankle brachial index; CRP: C-reactive protein; WBC: white blood cell; ESR: erythrocyte sedimentation rate; IL: interleukin; P-IL-6: IL-6 level in peripheral blood; P-IL-10: IL-10 level in peripheral blood.

**Additional file 2: Table S1.** Detection method of observation indices.

**Additional file 3: Table S2.** Specific primers and reaction conditions in qRT-PCR.

**Additional file 4: Table S3.** Comparison of vitamin D nutritional status in diabetes foot ulcers with different Wagner grades and infection severity.



### Acknowledgements

We are grateful to all the patients for participating in the study. We thank the participants of this study including the doctors, nurses, and researchers from the Department of Endocrinology in the First Affiliated Hospital of Anhui Medical University.

### Author contributions

YT was involved in the overall study, designed the analysis plan, analyzed the data, and wrote the manuscript. MX and XZ recruited and collected clinical samples. YH, LL and DD collected the data and analyzed the data. ZF and MC contributed to the discussion and reviewed the manuscript. All authors contributed to the article. All authors read and approved the final manuscript.

### Funding

This study was supported by the Natural Science Foundation of Anhui Province in China (2108085MH269), the Natural Science Research Project of Colleges and Universities in Anhui Province (KJ2021A0274), and Anhui University Cooperation and Public Health Collaborative Innovation Project (GXXT-2020-025). The funding body had no role in the design of the study, or the collection, analysis, and interpretation of data, or in writing the manuscript.

### Availability of data and materials

All data generated or analysed during this study and supporting our findings are included and can be found in the manuscript. The raw data can be provided by corresponding author on reasonable request.

### Declarations

#### Ethics approval and consent to participate

All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Anhui Medical University (Ethics batch number P2018-11-16), and informed consent was obtained from all participants.

#### Consent for publication

All authors have declared their consent for this publication.

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China. <sup>2</sup>Department of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China.

Received: 28 November 2022 Accepted: 17 February 2023

Published online: 24 February 2023

### References

1. Yazdanpanah L, Nasiri M, Adarvishi S. Literature review on the management of diabetic foot ulcer. *World J Diabetes*. 2015;6(1):37–53.
2. Lázaro Martínez JL, García Álvarez Y, Tardáguila-García A, García ME. Optimal management of diabetic foot osteomyelitis: challenges and solutions. *Diabetes Metab Syndr Obes*. 2019;12:947–59.
3. Lei M, Liu Z, Guo J. The emerging role of vitamin D and vitamin D receptor in diabetic nephropathy. *Biomed Res Int*. 2020;2020:4137268.
4. DeLuca HF. Overview of general physiologic features and functions of vitamin D. *Am J Clin Nutr*. 2004;80(6 Suppl):1689S–1696S.
5. Larson-Meyer DE, Willis KS. Vitamin D and athletes. *Curr Sports Med Rep*. 2010;9(4):220–6.
6. Dai J, Jiang C, Chen H, Chai Y. Vitamin D and diabetic foot ulcer: a systematic review and meta-analysis. *Nutr Diabetes*. 2019;9(1):8.
7. Yammine K, Hayek F, Assi C. Is there an association between vitamin D and diabetic foot disease? A meta-analysis. *Wound Repair Regen*. 2020;28(1):90–6.
8. Tiwari S, Pratyush DD, Gupta B, Dwivedi A, Chaudhary S, Rayicherla RK, Gupta SK, Singh SK. Prevalence and severity of vitamin D deficiency in patients with diabetic foot infection. *Br J Nutr*. 2013;109(1):99–102.
9. Danny Darlington CJ, Suresh Kumar S, Jagdish S, Sridhar MG. Evaluation of serum vitamin D levels in diabetic foot infections: a cross-sectional study in a tertiary care center in South India. *Iran J Med Sci*. 2019;44(6):474–82.
10. Kurian SJ, Miraj SS, Benson R, Munisamy M, Saravu K, Rodrigues GS, Rao M. Vitamin D supplementation in diabetic foot ulcers: a current perspective. *Curr Diabetes Rev*. 2021;17(4):512–21.
11. Razzaghi R, Pourbagheri H, Momen-Heravi M, Bahmani F, Shadi J, Soleimani Z, Asemi Z. The effects of vitamin D supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial. *J Diabetes Complications*. 2017;31(4):766–72.
12. Tsitsou S, Dimosthenopoulos C, Eleftheriadou I, Andrianesis V, Tentolouris N. Evaluation of vitamin D levels in patients with diabetic foot ulcers. *Int J Low Extrem Wounds*. 2021. <https://doi.org/10.1177/1534734620984584>.
13. Afarideh M, Ghanbari P, Noshad S, Ghajar A, Nakhjavani M, Esteghamati A. Raised serum 25-hydroxyvitamin D levels in patients with active diabetic foot ulcers. *Br J Nutr*. 2016;115(11):1938–46.
14. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, Teran-Soto JM, Fabian-Victoriano MR, Kresch-Tronik NS, Garrido-Espíndola X, Garcia-Solis A, Bondani-Guasti A, Bierzwinsky-Sneider G, Contreras-Ruiz J. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial. *Wound Repair Regen*. 2014;22(4):497–503.
15. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E, Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. 2012;54(12):e132–73.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130(6):461–70.
17. Holick MF. Resurrection of vitamin D deficiency and rickets. *J Clin Invest*. 2006;116(8):2062–72.
18. Pena G, Kuang B, Cowled P, Howell S, Dawson J, Philpot R, Fitridge R. Micronutrient status in diabetic patients with foot ulcers. *Adv Wound Care (New Rochelle)*. 2020;9(1):9–15.
19. Greenhagen RM, Frykberg RG, Wukich DK. Serum vitamin D and diabetic foot complications. *Diabet Foot Ankle*. 2019;10(1):1579631.
20. Wang F, Zhou L, Zhu D, Yang C. A retrospective analysis of the relationship between 25-OH-vitamin D and diabetic foot ulcer. *Diabetes Metab Syndr Obes*. 2022;15:1347–55.
21. Wenclewska S, Szymczak-Pajor I, Drzewoski J, Bunk M, Śliwińska A. Vitamin D supplementation reduces both oxidative DNA damage and insulin resistance in the elderly with metabolic disorders. *Int J Mol Sci*. 2019;20(12):2891.
22. Pei E, Li J, Lu C, Xu J, Tang T, Ye M, Zhang X, Li M. Effects of lipids and lipoproteins on diabetic foot in people with type 2 diabetes mellitus: a meta-analysis. *J Diabetes Complications*. 2014;28(4):559–64.
23. Richard JL, Sotto A, Jourdan N, Combescurc C, Vannereau D, Rodier M, Lavigne JP, Nimes University Hospital Working Group on the Diabetic Foot (GP30). Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. *Diabetes Metab*. 2008;34(4 Pt 1):363–9.
24. Schmidt BM, Ye W, Zhou S. Multidrug resistant organism predicts ulcer recurrence following surgical management of diabetic foot osteomyelitis. *Int Wound J*. 2020;17(6):1634–41.
25. Bishop EL, Ismailova A, Dimeloe S, Hewison M, White JH. Vitamin D and immune regulation: antibacterial, antiviral, anti-inflammatory. *JBM R Plus*. 2020;5(1): e10405.
26. Qiao Z, Li-Xing S, Nian-Chun P, Shu-Jing X, Miao Z, Hong L, Hui-Jun Z, Ming-Xian G, Song Z, Rui W, Ying H, Jing-Lu Z, Shuang C. Serum 25(OH) D level and parathyroid hormone in Chinese adult population: a cross-sectional study in Guiyang urban community from southeast of China. *Int J Endocrinol*. 2013;2013: 150461.
27. Knuschke P. Sun exposure and vitamin D. *Curr Probl Dermatol*. 2021;55:296–315.

28. Wu T, Xie D, Zhao X, Xu M, Luo L, Deng D, Chen M. Enhanced expression of miR-34c in peripheral plasma associated with diabetic foot ulcer in type 2 diabetes patients. *Diabetes Metab Syndr Obes.* 2021;14:4263–73.
29. He Y, Qian H, Xu L, Zhang S, Gu X, Gu J, Shi J, Shen Y, Liu J, Tang Z. Association between estimated glomerular filtration rate and outcomes in patients with diabetic foot ulcers: a 3-year follow-up study. *Eur J Endocrinol.* 2017;177(1):41–50.
30. Xiao Y, Wei L, Xiong X, Yang M, Sun L. Association between Vitamin D status and diabetic complications in patients with type 2 diabetes mellitus: a cross-sectional study in Hunan China. *Front Endocrinol (Lausanne).* 2020;11: 564738.
31. Dai J, Yu M, Chen H, Chai Y. Association between serum 25-OH-vitamin D and diabetic foot ulcer in patients with type 2 diabetes. *Front Nutr.* 2020;7:109.
32. Depczynski B, Young T, White C. A high ankle-brachial index is associated with obesity and low serum 25-hydroxyvitamin D in patients with diabetes. *J Clin Transl Endocrinol.* 2018;11:7–10.
33. He R, Hu Y, Zeng H, Zhao J, Zhao J, Chai Y, Lu F, Liu F, Jia W. Vitamin D deficiency increases the risk of peripheral neuropathy in Chinese patients with type 2 diabetes. *Diabetes Metab Res Rev.* 2017. <https://doi.org/10.1002/dmrr.2820>.
34. Davis FM, Kimball A, Boniakowski A, Gallagher K. Dysfunctional wound healing in diabetic foot ulcers: new crossroads. *Curr Diab Rep.* 2018;18(1):2.
35. Gonzalez-Curiel I, Trujillo V, Montoya-Rosales A, Rincon K, Rivas-Calderon B, deHaro-Acosta J, Marin-Luevano P, Lozano-Lopez D, Enciso-Moreno JA, Rivas-Santiago B. 1,25-Dihydroxyvitamin D3 induces LL-37 and HBD-2 production in keratinocytes from diabetic foot ulcers promoting wound healing: an in vitro model. *PLoS ONE.* 2014;9(10): e111355.
36. Xiong Y, Zhou F, Liu Y, Yi Z, Wang X, Wu Y, Gong P. 1 $\alpha$ , 25-Dihydroxyvitamin D3 promotes angiogenesis by alleviating AGEs-induced autophagy. *Arch Biochem Biophys.* 2021;712: 109041.
37. Yuan Y, Das SK, Li M. Vitamin D ameliorates impaired wound healing in streptozotocin-induced diabetic mice by suppressing NF- $\kappa$ B-mediated inflammatory genes. *Biosci Rep.* 2018;38(2): BSR20171294.
38. Yuan YF, Das SK, Li MQ. Vitamin D ameliorates impaired wound healing in streptozotocin-induced diabetic mice by suppressing endoplasmic reticulum stress. *J Diabetes Res.* 2018;2018:1757925.
39. Zhang X, Zhou M, Guo Y, Song Z, Liu B. 1,25-Dihydroxyvitamin D3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPAR $\gamma$  signaling pathway. *Biomed Res Int.* 2015;2015: 157834.
40. Small AG, Harvey S, Kaur J, Putty T, Quach A, Munawara U, Perveen K, McPhee A, Hii CS, Ferrante A. Vitamin D upregulates the macrophage complement receptor immunoglobulin in innate immunity to microbial pathogens. *Commun Biol.* 2021;4(1):401.
41. Lowry MB, Guo C, Zhang Y, Fantacone ML, Logan IE, Campbell Y, Zhang W, Le M, Indra AK, Ganguli-Indra G, Xie J, Gallo RL, Koeffler HP, Gombart AF. A mouse model for vitamin D-induced human cathelicidin antimicrobial peptide gene expression. *J Steroid Biochem Mol Biol.* 2020;198: 105552.
42. Soroush N, Radfar M, Hamidi AK, Abdollahi M, Qorbani M, Razi F, Esfahani EN, Amoli MM. Vitamin D receptor gene FokI variant in diabetic foot ulcer and its relation with oxidative stress. *Gene.* 2017;599:87–91.
43. Li X, Tang Y, Jia Z, Zhao X, Chen M. Decreased expression of miR-24 in peripheral plasma of type 2 diabetes mellitus patients associated with diabetic foot ulcer. *Wound Repair Regen.* 2020;28(6):728–38.
44. Shekhar C. An innovative technique in local antibiotic delivery method in open infected wounds of the musculoskeletal system. *Int J Low Extrem Wounds.* 2019;18(2):153–60.
45. Marschall J, Lewis JW, Warren DK, Babcock HM, Barrack RL, Fraser VJ. Baseline hypovitaminosis D is not associated with poor clinical outcomes in osteoarticular infections. *Int J Infect Dis.* 2014;26:98–102.
46. Li ZF, Cao LH, Wang Y, Zhang Z, Fan MW, Xu QA. Inhibitory effect of 1,25-dihydroxyvitamin D3 on Porphyromonas gingivalis-induced inflammation and bone resorption in vivo. *Arch Oral Biol.* 2016;72:146–56.
47. Maiti A, Jiranek WA. Inhibition of Methicillin-resistant Staphylococcus aureus-induced cytokines mRNA production in human bone marrow derived mesenchymal stem cells by 1,25-dihydroxyvitamin D3. *BMC Cell Biol.* 2014;15:11.
48. Jiang N, Zhao XQ, Qin CH, Hu YJ, Wang L, Xie GP, Wang SN, Chen LG, Yu B. Association of vitamin D receptor gene TaqI, BsmI, FokI and ApaI polymorphisms and susceptibility to extremity chronic osteomyelitis in Chinese population. *Injury.* 2016;47(8):1655–60.
49. Ouma S, Suenaga M, Bölükbaş Hatip FF, Hatip-Al-Khatib I, Tsuboi Y, Matsunaga Y. Serum vitamin D in patients with mild cognitive impairment and Alzheimer's disease. *Brain Behav.* 2018;8(3): e00936.
50. Lin S, Wang Y, Li L, Chen P, Mao R, Feng R, Qiu Y, He Y, Chen B, Zeng Z, Chen M, Zhang S. A new model based on 25-hydroxyvitamin D3 for predicting active crohn's disease in Chinese patients. *Mediat Inflamm.* 2018;2018:3275025.
51. Erdoğan M, Fındıklı HA. Novel biomarker for predicting sepsis mortality: vitamin D receptor. *J Int Med Res.* 2021;49(8):3000605211034733.
52. Ding P, Du X, Wan L, Zhao X, Zhang D, Huang Z, Cao G, Zhou X, Zheng Y, Cao Y. Diagnostic value of VDR in bone metastasis and prognosis of patients with breast cancer and expression correlation between vitamin D receptor and hairless protein. *Oncol Res Treat.* 2022;45(4):166–77.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

